OCS
NASDAQ · Pharmaceuticals
Oculis Holding Ag
$25.10
+0.58 (+2.37%)
Financial Highlights (FY 2025)
Revenue
335.81M
Net Income
75.81M
Gross Margin
45.7%
Profit Margin
22.6%
Rev Growth
+1.2%
D/E Ratio
0.56
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 45.7% | 45.7% | 45.7% |
| Operating Margin | 26.7% | 29.6% | 27.6% |
| Profit Margin | 22.6% | 22.5% | 22.5% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 335.81M | 321.14M | 281.93M |
| Gross Profit | 153.35M | 146.65M | 128.74M |
| Operating Income | 89.51M | 95.11M | 77.82M |
| Net Income | 75.81M | 72.36M | 63.56M |
| Gross Margin | 45.7% | 45.7% | 45.7% |
| Operating Margin | 26.7% | 29.6% | 27.6% |
| Profit Margin | 22.6% | 22.5% | 22.5% |
| Rev Growth | +1.2% | -6.4% | +18.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 316.00M | 325.49M | 320.75M |
| Total Equity | 562.30M | 501.72M | 538.47M |
| D/E Ratio | 0.56 | 0.65 | 0.60 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 137.16M | 117.64M | 104.92M |
| Free Cash Flow | 80.35M | 48.21M | 59.98M |